stereOtactic Body RadIothErapy for exTracranial oligomeTastAtic Breast Cancer: Multi Institutional Retrospective Database

NCT07397585 — Recruiting, 300 participants, Istituto Clinico Humanitas

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT07397585, acronym ORIETTA
StatusRecruiting
Study typeObservational
Enrollment300 (Estimated)
SponsorIstituto Clinico Humanitas (Other)
ConditionsBreast Cancer, Oligometastasis
Datesstart 2025-02-25, primary completion 2026-12-31 (estimated), completion 2026-12-31 (estimated), first posted 2026-02-09, last updated 2026-02-11
Locations28 sites in Italy

Related Papers Related Patents Related Grants Related Experts
All trials for Breast Cancer All trials for Oligometastasis

-Summary

Oligometastatic breast cancer is a condition in which breast cancer has spread to a small number of other parts of the body. Patients with this type of disease may live longer than those with more widespread metastases. In addition to standard treatments that act on the whole body, such as chemotherapy or hormonal therapy, these patients might also benefit from local treatments that directly target the cancer spots. One of these local treatments is stereotactic body radiotherapy (SBRT), a non-invasive radiation treatment that delivers high doses of radiation in a few sessions. In the past, most of the evidence about the benefit of local treatments came from surgery. More recently, there has been growing interest in SBRT because it does not require surgery. However, the results of studies so far have not been consistent.The goal of this multicenter retrospective study is to better understand whether SBRT can improve disease control and survival in patients with breast cancer that has spread to a limited number of sites outside the brain.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
TREATMENT SBRTpatients who have been treated with stereotactic radiotherapy to oligometastatic sites

+Outcome measures

Primary outcomes

  • progression free survival [from January 2010 to December 2023]: years of survival without disease progression assessed by imaging

Secondary outcomes

  • Local Control [from January 2010 to December 2023]: time between treatment and disease recurrence assessed by imaging
  • overall survival [From January 2010 to December 2023]: the time from diagnosis or initiation of treatment until death from any cause
  • acute and late toxicity RT related [from January 2010 to December 2023]: Evaluation of toxicities related to radiotherapy treatment using the scale CTCAE (Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe, Grade 4: Life-threatening, Grade 5: Death)

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Patients ≥18 years
* Histological diagnosis of breast cancer
* Oligometastatic or oligoprogressive metastatic breast cancer
* SBRT delivered to a minimum dose of 50Gy EQD2 (αβ 10 Gy),in a maximum of 12 fractions as per Oligocare definition
* Ability to provide written informed consent

+Locations (28)

FacilityCityCountryStatus
Aorn San PioBenevento, BeneventoItalyNot yet recruiting
Humanitas GavazzeniBergamo, BergamoItalyRecruiting
Ospedale PerrinoBrindisi, BRItalyNot yet recruiting
Spedali CiviliBrescia, BSItalyRecruiting
Responsible Research HospitalCampobasso, CBItalyRecruiting
Azienda Ospedaliera Universitaria CareggiFlorence, FirenzeItalyNot yet recruiting
Irccs Ospedale Policlinico San MartinoGenova, GenovaItalyNot yet recruiting
A.O.U. "G. Martino" - Università degli Studi di MessinaMessina, MessinaItalyNot yet recruiting
Fondazione I.R.C.C.S Istituto Nazionale Tumori di MilanoMilan, MILANOItalyRecruiting
IEOMilan, MilanoItalyNot yet recruiting
IRCCS Humanitas Research HumanitasRozzano, MILANOItalyRecruiting
IRCCS Ospedale San RaffaeleMilan, MilanItalyNot yet recruiting
INT IRCCS Fondazione G. PascaleNaples, NapoliItalyRecruiting
Ospedale Maggiore della CaritaNovara, NOVARAItalyRecruiting
Civico PalermoPalermo, PalermoItalyNot yet recruiting
Istituto Oncologico VenetoPadova, PDItalyNot yet recruiting
Azienda Ospedaliera Universitaria PisanaPisa, PIItalyNot yet recruiting
IRCCS Centro di Riferimento Oncologico di AvianoAviano, PordenoneItalyNot yet recruiting
Uo Radioterapia Aor San CarloPotenza, PZItalyNot yet recruiting
Irccs CrobRionero in Vulture, PZItalyRecruiting
UOC Radioterapia Ospedale San Filippo NeriRoma, RMItalyNot yet recruiting
Azienda Ospedaliera San Giovanni AddolorataRoma, RMItalyNot yet recruiting
Fondazione Policlinico Universitario, Campus-BiomedicoRoma, RomaItalyRecruiting
Fondazione PTV Policlinico Tor VergataRoma, RomaItalyNot yet recruiting
Azienda Ospedaliera Sant'AndreaRoma, RomaItalyNot yet recruiting
S.C. Radioterapia Oncologica ASL TarantoTaranto, TarantoItalyNot yet recruiting
Radioterapia Oncologica - Ospedale Sanata ChiaraTrento, TRENTOItalyNot yet recruiting
S.C. Radioterapia Oncologica - Azienda Ospedaliera Santa Maria TerniTerni, TRItalyNot yet recruiting

+Publications

  • van Ommen-Nijhof A, Steenbruggen TG, Capel L, Vergouwen M, Vrancken Peeters MT, Wiersma TG, Sonke GS. Survival and prognostic factors in oligometastatic breast cancer. Breast. 2023 Feb;67:14-20. doi: 10.1016/j.breast.2022.12.007. Epub 2022 Dec 14. PMID 36549169
  • K. A. W. W. A. W. V. F. B. J. K. Steven J. Chmura, "NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer," ASCO, 2022
  • Harrow S, Palma DA, Olson R, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Senthi S, Swaminath A, Kopek N, Liu M, Schlijper R, Bauman GS, Laba J, Qu XM, Warner A, Senan S. Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes. Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):611-616. doi: 10.1016/j.ijrobp.2022.05.004. Epub 2022 May 26. PMID 35643253
  • Terao M, Niikura N. Diagnosis of oligometastasis. Transl Cancer Res. 2020 Aug;9(8):5032-5037. doi: 10.21037/tcr.2020.01.04. PMID 35117868